Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation

The molecular chaperone Clusterin (CLU) impacts the amyloid pathway in Alzheimer’s disease (AD) but its role in tau pathology is unknown. We observed CLU co-localization with tau aggregates in AD and primary tauopathies and CLU levels were upregulated in response to tau accumulation. To further eluc...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Acta Neuropathol Commun
Main Authors: Wojtas, Aleksandra M., Carlomagno, Yari, Sens, Jonathon P., Kang, Silvia S., Jensen, Tanner D., Kurti, Aishe, Baker, Kelsey E., Berry, Taylor J., Phillips, Virginia R., Castanedes, Monica Casey, Awan, Ayesha, DeTure, Michael, De Castro, Cristhoper H. Fernandez, Librero, Ariston L., Yue, Mei, Daughrity, Lillian, Jansen-West, Karen R., Cook, Casey N., Dickson, Dennis W., Petrucelli, Leonard, Fryer, John D.
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2020
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7708249/
https://ncbi.nlm.nih.gov/pubmed/33261653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40478-020-01079-1
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים